** Shares of telehealth firm WW International WW.O rise 8.5% to $41.50 premarket
** Co, also known as WeightWatchers, reports its clinical subscription revenue rose 55.1% during the quarter ended June 30, driven by compounded semaglutide subscriptions
** Says from May 22, it began transitioning subscribers from compounded semaglutide to FDA-approved medications, in line with current FDA guidance
** Co, forecasts 2025 total revenue to be in the range of $685 million to $700 million
** Forecasts adj. core profit to be in the range of $140 million to $150 million
** Co has not previously provided a forecast for 2025
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。